Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Immunome, Inc. (IMNM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$17.91-8.25%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IMNM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain cash to fund operations through 2028 | The company aims to fund operations through 2028, supporting continued development. | Intact | Company fails to maintain cash to fund operations through 2028 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 1 supplied quarters. Management reported: “Immunome expects its current cash position to fund operations into 2028.” “First Quarter 2026 Financial Results • As of March 31, 2026, cash and cash equivalents totaled $582.7 million .” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotech, not an established earnings compounder. The long-term thesis is in a watch state: pipeline milestones have advanced, but recent financial performance is weak and the business remains loss-making.
The valuation is about 17.7% above peers, with low confidence in the valuation model and pipeline optionality as the main reason for the difference. The evidence does not show that weak results are fully reflected in expectations, though the priced-in fragility assessment is low.
Near term, continued losses and cash use are likely as management advances clinical trials; cash declined from $653.5 million to $582.7 million in the first quarter of 2026, while management expects funding into 2028. The NDA submission for varegacestat and positive topline RINGSIDE results mark progress, but the next report carries elevated miss risk and recent performance trails the industry cohort.
Over the multi-year view, the key question is whether pipeline progress, including the detailed Phase 3 RINGSIDE data and trials for IM-1021, IM-1617, and IM-3050, can support the development strategy. Near term, guidance and cash use matter; weakening employment data could pressure healthcare names, while strong results from sector peers could improve the backdrop.
IMNM's multi-year thesis rests on clinical execution and keeping operations funded into 2028, against a backdrop of ongoing losses, elevated risk, and a valuation premium to peers. The evidence is mixed, so the thesis remains in a watch state. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce losses and improve EPS trajectory | A supporting condition in Immunome, Inc.'s published investment case. The stated target is EPS loss narrows toward -$2.1 or better in FY26 and FY27. | Intact | EPS loss worsens beyond -$2.1 in FY26 or FY27 | Diluted EPS: $-0.65 per share FY2026-Q2; GAAP. Published target: EPS loss narrows toward -$2.1 or better in FY26 and FY27. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 11, 2026-0.65 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Positive Phase 3 RINGSIDE trial data for varegacestat | Immunome is developing antibody therapies with promising Phase 3 data for varegacestat. | Under Pressure | Negative Phase 3 RINGSIDE data undermines trial objectives | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.18 → $-2.51 · observed estimates
$0.06B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-07-25 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-07-26 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-07-27 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-07-28 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-07-29 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-07-30 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-07-31 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-08-01 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-02 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-08-03 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-04 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-08-05 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-08-06 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-08-07 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-08 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-08-09 | $-2.12 | $64,623,090 | 11 / 11 |
| 2026-08-10 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-12 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-13 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-14 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-15 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-16 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-17 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-18 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-19 | $-2.18 | $56,307,893 | 9 / 8 |
| 2026-08-20 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-21 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-22 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-23 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-24 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-25 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-26 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-27 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-28 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-29 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-30 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-08-31 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-09-01 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-09-02 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-09-03 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-09-04 | $-2.47 | $53,346,357 | 9 / 8 |
| 2026-09-05 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-06 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-07 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-08 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-09 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-10 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-11 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-12 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-13 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-14 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-15 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-16 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-17 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-18 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-19 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-20 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-21 | $-2.47 | $53,349,267 | 9 / 8 |
| 2026-09-22 | $-2.42 | $52,235,161 | 9 / 9 |
| 2026-09-23 | $-2.42 | $52,235,161 | 9 / 9 |
| 2026-09-24 | $-2.42 | $52,235,161 | 9 / 9 |
| 2026-09-25 | $-2.42 | $52,235,161 | 10 / 9 |
| 2026-09-26 | $-2.42 | $52,235,161 | 10 / 9 |
| 2026-09-27 | $-2.42 | $52,235,161 | 10 / 9 |
| 2026-09-28 | $-2.42 | $52,235,161 | 10 / 9 |
| 2026-09-29 | $-2.42 | $52,235,161 | 10 / 9 |
| 2026-09-30 | $-2.42 | $52,235,161 | 10 / 9 |
| 2026-10-01 | $-2.46 | $51,981,302 | 10 / 9 |
| 2026-10-02 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-03 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-04 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-05 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-06 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-07 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-08 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-09 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-10 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-11 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-12 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-13 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-14 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-15 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-16 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-17 | $-2.43 | $51,981,302 | 10 / 10 |
| 2026-10-18 | $-2.45 | $48,675,495 | 11 / 11 |
| 2026-10-19 | $-2.45 | $48,675,495 | 11 / 11 |
| 2026-10-20 | $-2.45 | $48,675,495 | 11 / 11 |
| 2026-10-21 | $-2.45 | $48,675,495 | 11 / 11 |
| 2026-10-22 | $-2.45 | $48,675,495 | 11 / 11 |
| 2026-10-23 | $-2.43 | $48,675,495 | 11 / 11 |
| 2026-10-24 | $-2.43 | $48,675,495 | 11 / 11 |
| 2026-10-25 | $-2.43 | $48,675,495 | 11 / 11 |
| 2026-10-26 | $-2.46 | $48,675,495 | 11 / 11 |
| 2026-10-27 | $-2.46 | $48,675,495 | 11 / 11 |
| 2026-10-28 | $-2.49 | $48,675,495 | 11 / 11 |
| 2026-10-29 | $-2.49 | $48,675,495 | 11 / 11 |
| 2026-10-30 | $-2.49 | $48,675,495 | 11 / 11 |
| 2026-10-31 | $-2.49 | $48,675,495 | 11 / 11 |
| 2026-11-01 | $-2.49 | $48,675,495 | 11 / 11 |
| 2026-11-02 | $-2.49 | $48,675,495 | 11 / 11 |
| 2026-11-03 | $-2.49 | $48,675,495 | 11 / 11 |
| 2026-11-04 | $-2.51 | $48,675,495 | 11 / 11 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 16 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.